Marchetti Matteo, Spagnol Giulia, Vezzaro Tommaso, Bigardi Sofia, De Tommasi Orazio, Facchetti Emma, Tripepi Marta, Costeniero Diletta, Munerol Chiara, Maggino Tiziano, D'Antona Donato, Tozzi Roberto, Saccardi Carlo, Noventa Marco
Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Cancers (Basel). 2024 Sep 21;16(18):3221. doi: 10.3390/cancers16183221.
(1) Background: Endometrial carcinoma (EC) classified as no specific molecular profile (NSMP) represents a heterogeneous group with variable prognoses. This retrospective, single-center study aims to further stratify NSMP ECs to tailor treatment strategies and improve outcomes. (2) Methods: From 2020 to 2023, we collected data on 51 patients diagnosed with NSMP EC following the introduction of molecular profiling at our institution. Patients were retrospectively analyzed for estrogen receptor (ER) status, histotype, and grade to identify potential prognostic subgroups. (3) Results: Our analysis identified two distinct subgroups within NSMP EC: low-risk and high-risk, based on ER status, histotype, and grade. The low-risk NSMP group demonstrated significantly better survival outcomes compared to the high-risk group. With a median follow-up time of 16 moths (IQR 13.0-29.7), the disease-free survival (DFS) and overall survival (OS) for the low-risk group were 100%. For the high-risk group, the DFS and OS were 71.4% and 78.6%, respectively, which showed a statistically significantly difference (Log-Rank Mantel-Cox < 0.001). In the high-risk group, four patients experienced recurrence, and three of these patients died. (4) Conclusions: Stratifying NSMP EC into low-risk and high-risk categories based on ER status, histotype, and grade can lead to more accurate prognostic assessments. In time, it may require tailored adjuvant therapies and a personalized treatment.
(1) 背景:归类为无特定分子特征(NSMP)的子宫内膜癌(EC)是一个预后各异的异质性群体。这项回顾性单中心研究旨在进一步对NSMP EC进行分层,以制定治疗策略并改善治疗效果。(2) 方法:2020年至2023年,我们收集了在本机构引入分子特征分析后被诊断为NSMP EC的51例患者的数据。对患者进行回顾性分析,以确定雌激素受体(ER)状态、组织学类型和分级,从而识别潜在的预后亚组。(3) 结果:我们的分析基于ER状态、组织学类型和分级,在NSMP EC中确定了两个不同的亚组:低风险组和高风险组。低风险NSMP组的生存结果明显优于高风险组。中位随访时间为16个月(IQR 13.0 - 29.7),低风险组的无病生存期(DFS)和总生存期(OS)均为100%。高风险组的DFS和OS分别为71.4%和78.6%,差异具有统计学意义(Log-Rank Mantel-Cox < 0.001)。在高风险组中,有4例患者复发,其中3例死亡。(4) 结论:根据ER状态、组织学类型和分级将NSMP EC分为低风险和高风险类别,可以实现更准确的预后评估。及时地说,这可能需要定制辅助治疗和个性化治疗。